116.01USD+1.77%Mkt Cap: 1.67B USDP/E: —Last update: 2026-05-26
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product cand…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.67B USD
Enterprise Value1.42B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-41.72M USD
Revenue/Share—
Last Price116.01 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.35
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B51.29
EPS (TTM)-4.17
EPS (Forward)-6.68
52W Range
20.2073% of range151.18
52W High151.18 USD
52W Low20.20 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-149.07%
ROA-70.04%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.01M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.30%
Net Debt-241.47M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.02
Current Ratio28.88
Quick Ratio28.73
Book Value/Sh2.260 USD
Cash/Share18.26 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:80
Split DateApr 23, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)229.00 USD
Target Range205.00 USD – 270.00 USD
# Analysts16
Ownership
Shares Out.14.34M
Float9.58M
Insiders11.65%
Institutions95.93%
Short Interest
Short Ratio9.1d
Short % Float17.16%
Short % Out.15.15%
Shares Short2.17M
Short (prev mo.)2.18M
Technical
SMA 50122.27 (-5.1%)
SMA 20091.67 (+26.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)211.76K
Avg Vol (10d)222.90K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—